Literature DB >> 22469793

Outcomes from IBD-associated and non-IBD-associated colorectal cancer: a Surveillance Epidemiology and End Results Medicare study.

Susan L Gearhart1, Hari Nathan, Timothy M Pawlik, Elizabeth Wick, Jonathan Efron, Andrew D Shore.   

Abstract

BACKGROUND: There is controversy as to whether the clinicopathological features of colorectal cancer in the setting of IBD are distinct from sporadic colorectal cancer.
OBJECTIVE: The aim of this study was to compare the characteristics and outcomes between IBD-associated and sporadic colorectal cancer.
DESIGN: This retrospective population-based cohort study used the Surveillance, Epidemiology, and End Results Medicare-linked database. SETTINGS: This study was conducted in 6 US metropolitan areas enrolled in Surveillance, Epidemiology, and End Results. PATIENTS: Beneficiaries of Medicare parts A and B identified from the Surveillance, Epidemiology, and End Results database with a diagnosis of IBD-associated or sporadic colorectal cancer who underwent surgical resection were included in the study. MAIN OUTCOMES MEASURES: The main outcome was death. The adjusted risk ratio for death compared patients with IBD-associated colorectal cancer with patients who had sporadic colorectal cancer.
RESULTS: Patients with IBD-associated colorectal cancer were more likely to present at an earlier stage, use immunosuppression, and have metachronous colorectal cancer. Although total proctocolectomy was more common among IBD patients with colorectal cancer, the majority (>75%) underwent a segmental resection. Cancer-specific survival was worse for IBD-associated colorectal cancer vs sporadic colorectal cancer (mean, 32.9 months vs 42.4 months). After adjusting for potential confounders, older age, male sex, higher stage, IBD, immunosuppression, neoadjuvant radiation, and metachronous tumor were associated with a higher risk of cancer-specific mortality. Among patients with IBD, there was no difference in cancer-specific survival for segmental colectomy vs proctocolectomy. LIMITATIONS: This is a retrospective cohort study utilizing insurance data dependent on the correct coding of patient claims.
CONCLUSION: Older patients with IBD-associated colorectal cancer appear to have a slightly worse outcome than those with sporadic colorectal cancer. The cause of this is multifactorial, but it does not appear to be associated with a more limited surgical resection.

Entities:  

Mesh:

Year:  2012        PMID: 22469793     DOI: 10.1097/DCR.0b013e318242620f

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  14 in total

1.  Prognosis of Colorectal Cancer in Inflammatory Bowel Disease: Data from a State Registry.

Authors:  Thomas A Ullman; Steven H Itzkowitz
Journal:  Dig Dis Sci       Date:  2017-04-03       Impact factor: 3.199

Review 2.  Clinical outcomes and management of inflammatory bowel disease in the older patient.

Authors:  Christina Y Ha; Seymour Katz
Journal:  Curr Gastroenterol Rep       Date:  2013-02

Review 3.  A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer.

Authors:  Ian S Reynolds; Aobhlinn O'Toole; Joseph Deasy; Deborah A McNamara; John P Burke
Journal:  Int J Colorectal Dis       Date:  2017-01-11       Impact factor: 2.571

4.  Survival of Colorectal Cancer in Patients With or Without Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Baochi Ou; Jingkun Zhao; Shaopei Guan; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

5.  An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer.

Authors:  Bríd M Ryan; Roger K Wolff; Nicola Valeri; Mohammed Khan; Dillon Robinson; Alessio Paone; Elise D Bowman; Abbie Lundgreen; Bette Caan; John Potter; Derek Brown; Carlo Croce; Martha L Slattery; Curtis C Harris
Journal:  Cancer Epidemiol       Date:  2014-08-15       Impact factor: 2.984

6.  Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah.

Authors:  N Jewel Samadder; John F Valentine; Stephen Guthery; Harminder Singh; Charles N Bernstein; Yuan Wan; Jathine Wong; Kenneth Boucher; Lisa Pappas; Kerry Rowe; Mary Bronner; Cornelia M Ulrich; Randall W Burt; Karen Curtin; Ken R Smith
Journal:  Dig Dis Sci       Date:  2017-01-03       Impact factor: 3.199

Review 7.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 8.  Inflammatory bowel disease associated neoplasia: A surgeon's perspective.

Authors:  Azah A Althumairi; Mark G Lazarev; Susan L Gearhart
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

9.  Hederagenin from the leaves of ivy (Hedera helix L.) induces apoptosis in human LoVo colon cells through the mitochondrial pathway.

Authors:  Bao-Xin-Zi Liu; Jin-Yong Zhou; Yu Li; Xi Zou; Jian Wu; Jun-Fei Gu; Jia-Rui Yuan; Bing-Jie Zhao; Liang Feng; Xiao-Bin Jia; Rui-Ping Wang
Journal:  BMC Complement Altern Med       Date:  2014-10-24       Impact factor: 3.659

10.  A thirty-year follow-up surveillance study for neoplasia of a dutch ulcerative colitis cohort.

Authors:  J A M Stolwijk; A M J Langers; J C Hardwick; R A Veenendaal; H W Verspaget; R A van Hogezand; H F Vasen; A E van der Meulen-de Jong
Journal:  ScientificWorldJournal       Date:  2013-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.